Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.67M | 6.47M | 35.54M | 5.18M | 19.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.67M | 6.47M | 35.54M | 5.18M | 19.22M |
| Cost of Revenue | 101.11M | 100.39M | 110.22M | 135.75M | 148.80M |
| Gross Profit | -93.44M | -93.91M | -74.68M | -130.57M | -129.57M |
| SG&A Expenses | 41.53M | 34.59M | 42.17M | 41.63M | 46.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.64M | 134.98M | 152.39M | 177.38M | 195.45M |
| Operating Income | -134.97M | -128.51M | -116.85M | -172.20M | -176.23M |
| Income Before Tax | -131.01M | -122.11M | -108.10M | -162.25M | -171.90M |
| Income Tax Expenses | -1.00K | -4.60M | 20.00K | 3.00K | -- |
| Earnings from Continuing Operations | -131.01M | -117.50M | -108.12M | -162.25M | -171.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.01M | -117.50M | -108.12M | -162.25M | -171.90M |
| EBIT | -134.97M | -128.51M | -116.85M | -172.20M | -176.23M |
| EBITDA | -116.80M | -108.83M | -97.37M | -151.16M | -152.38M |
| EPS Basic | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 |
| Normalized Basic EPS | -0.15 | -0.14 | -0.14 | -0.23 | -0.26 |
| EPS Diluted | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 |
| Normalized Diluted EPS | -0.15 | -0.14 | -0.14 | -0.23 | -0.26 |
| Average Basic Shares Outstanding | 532.46M | 529.30M | 526.72M | 446.99M | 417.36M |
| Average Diluted Shares Outstanding | 532.46M | 529.30M | 526.72M | 446.99M | 417.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |